Skip to main content
Clinical Trials/NCT02746068
NCT02746068
Unknown
Phase 3

COAST -1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study. A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects With Knee Osteoarthritis Associated With Bone Marrow Lesions.

Axsome Therapeutics, Inc.3 sites in 1 country346 target enrollmentMarch 2016

Overview

Phase
Phase 3
Intervention
AXS-02
Conditions
Osteoarthritis, Knee
Sponsor
Axsome Therapeutics, Inc.
Enrollment
346
Locations
3
Primary Endpoint
Change in patient reported pain intensity
Last Updated
7 years ago

Overview

Brief Summary

This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in subjects with knee osteoarthritis associated with bone marrow lesions.

Registry
clinicaltrials.gov
Start Date
March 2016
End Date
December 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male at least 50 years of age, or postmenopausal female
  • Meets the ACR clinical criteria for knee osteoarthritis
  • Bone Marrow Lesion of the knee present on MRI
  • Additional criteria may apply

Exclusion Criteria

  • Previous surgery on index knee
  • Any prior use of bisphosphonates within 6 months of screening
  • Additional criteria may apply

Arms & Interventions

AXS-02

Administered orally in the morning for 6 weeks

Intervention: AXS-02

Placebo

Administered orally in the morning for 6 weeks

Intervention: Placebo

Outcomes

Primary Outcomes

Change in patient reported pain intensity

Time Frame: Baseline to Week 24

Patient reported pain intensity is recorded as an average daily pain intensity using an 11-point scale (0 = no pain to 10 = worst pain possible)

Secondary Outcomes

  • Patient Global Impression of Change (PGI-C)(Week 12 and Week 24)
  • Change in WOMAC pain and stiffness subscales over time(Baseline to Week 24)
  • Clinical Global Impression of Change (CGI-C) scores(Week 12 and Week 24)

Study Sites (3)

Loading locations...

Similar Trials